The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the pheochromocytoma market’s growth in recent years?
The growing incidence rate of tumors is expected to propel the growth of the pheochromocytoma market going forward. Tumors are abnormal growths of cells that can be benign (non-cancerous) or malignant (cancerous). The rising cases of tumors and cancers emphasize the need for growing medical awareness, accurate diagnosis and tailored treatment strategies for managing desmoid pheochromocytoma effectively. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, reflecting a growth of 3.16% from 1,898,160 in 2021. Therefore, the growing incidence rate of tumors will drive the growth of the pheochromocytoma market going forward.
Pheochromocytoma Market Driver: Rising Occurrence Of Neuroendocrine Diseases To Fuel Pheochromocytoma Market Growth
The increasing occurrence of neuroendocrine diseases is anticipated to drive the future growth of the pheochromocytoma market going forward. Neuroendocrine diseases refer to a group of medical conditions that affect the neuroendocrine system, which is a complex network of nerve cells and glands that produce and regulate hormones. The rising occurrence of neuroendocrine diseases, including pheochromocytomas, can potentially drive demand for specialized diagnostics, treatments, surgeries, pharmaceuticals, and patient support services specific to this condition. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, the annual incidence of neuroendocrine diseases such as pheochromocytoma is estimated to range from 2 to 8 cases per 1 million individuals, with approximately 15% of these cases being cancerous. Moreover, the 5-year relative survival rate for recurrent or metastatic pheochromocytomas is projected to be within the range of 34% to 60%. Therefore, the increasing prevalence of neuroendocrine diseases will drive the growth of the pheochromocytoma market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12909&type=smp
How does the future projection of the pheochromocytoma market size compare to its historical growth?
The pheochromocytoma market size has grown steadily in recent years. It will grow from $3.03 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, increasing diagnosis and awareness, genetic research, government initiatives.
The pheochromocytoma market size is expected to see steady growth in the next few years. It will grow to $3.74 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to demand for combination therapies, investment in pheochromocytoma research and development, demand for minimally invasive pheochromocytoma treatments, high rare disease research initiatives. Major trends in the forecast period include increase in the number of drugs in clinical trials, advancements in diagnosis and treatment options, growing expertise in gene therapy, advancements in medical imaging.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12909&type=smp
Which key players are shaping the future of the pheochromocytoma market?
Major companies operating in the pheochromocytoma market are Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., Teva Pharmaceutical Company Limited, Mylan N.V., Bausch Health Companies Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Apotex Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Endo International PLC, Exelixis Inc., Lupin Limited, Lantheus Holdings Inc., Curium Pharma, ANI Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., WellSpring Pharmaceutical Corporation, HRA Pharma SE.
What trends will propel the growth and evolution of the pheochromocytoma market?
Major companies operating in the pheochromocytoma market are conducting clinical trials to test new treatment approaches, therapies and medications for pheochromocytoma, leading to the development of more effective and targeted treatments and improving patient outcomes. For instance, in August 2022, Novartis AG, a Switzerland-based pharmaceutical company, launched Phase 2 of a multicenter open-label study to assess the safety and dosimetry of Lutathera in adolescents aged 12 to under 18 with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pheochromocytoma and paragangliomas (PPGL). The research involves a multicenter, open-label, single-arm approach, such as an exploratory PPGL cohort that aims to include as many adolescents with PPGL as possible.
Which regions are expected to become dominant players in the pheochromocytoma market?
North America was the largest region in the pheochromocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pheochromocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report
What are the emerging key segments in the pheochromocytoma market, and how are they evolving?
The pheochromocytoma market covered in this report is segmented –
1) By Type: Adrenal Pheochromocytoma, Extra-Adrenal Pheochromocytoma
2) By Treatment: Medication, Surgery, Radionuclide Treatment, Other Treatments
3) By Diagnosis: Laboratory Tests, Imaging Tests, Genetic Testing
4) By End Users: Hospitals, Clinics, Research And Academic Institutes, Other End Users
Subsegments:
1) By Adrenal Pheochromocytoma: Unilateral Adrenal Pheochromocytoma, Bilateral Adrenal Pheochromocytoma
2) By Extra-Adrenal Pheochromocytoma: Paraganglioma, Paraganglioma, Paraganglioma
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12909
How is the pheochromocytoma market defined, and what are its core characteristics?
Pheochromocytoma is a rare tumor that forms in the center of one or both adrenal glands. These tumors arise from the adrenal medulla cells, which are responsible for producing hormones such as adrenaline (epinephrine) and noradrenaline (norepinephrine). Pheochromocytomas can lead to excessive secretion of these hormones, causing symptoms like high blood pressure, rapid heartbeat, anxiety and related effects.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
